



## Ethamsylate

## Chemical Properties

CAS No. :	2624-44-4
Formula:	C <sub>10</sub> H <sub>17</sub> NO <sub>5</sub>
Molecular Weight:	263.31
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Ethamsylate (Dicyclic) usually is used as a hemostatic drug, which increases capillary endothelial resistance and platelet adhesion, and inhibits biosynthesis and action of prostaglandins.
Targets(IC50)	Prostaglandin Receptor
In vitro	High concentrations of Ethamsylate were able to remove superoxide radicals. In the presence of Ethamsylate, arachidonic acid, thromboxane A <sub>2</sub> , collagen, and the calcium carrier A23187 promoted the induction of human platelet aggregation and the release of ATP. Ethamsylate inhibited the production of prostaglandins in the microsomes of pregnant women's uterine myometrium at an IC <sub>50</sub> of 0.5 mM. Ethamsylate was highly effective in inhibiting hydroxyl radicals (OH $\cdot$ ) at concentrations of 0.1-10 $\mu$ M.
In vivo	High concentrations of Ethamsylate were able to remove superoxide radicals. In the presence of Ethamsylate, arachidonic acid, thromboxane A <sub>2</sub> , collagen, and the calcium carrier A23187 promoted the induction of human platelet aggregation and the release of ATP. Ethamsylate inhibited the production of prostaglandins in the microsomes of pregnant women's uterine myometrium at an IC <sub>50</sub> of 0.5 mM. Ethamsylate was highly effective in inhibiting hydroxyl radicals (OH $\cdot$ ) at concentrations of 0.1-10 $\mu$ M.

## Solubility Information

Solubility	DMSO: 50 mg/mL (189.89 mM), Sonication is recommended. ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.5 mg/mL (9.49 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	3.7978 mL	18.989 mL	37.978 mL
5 mM	0.7596 mL	3.7978 mL	7.5956 mL
10 mM	0.3798 mL	1.8989 mL	3.7978 mL
50 mM	0.076 mL	0.3798 mL	0.7596 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

#### Reference

Kovács L, et al. *Experientia*, 1981, 37(11), 1182-1183

Garay RP, et al. *Am J Ther*, 2006, 13(3), 236-247.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481